Previous research conducted recent years used flagellin in the development of tumor vaccines, and one such study demonstrated enhanced tumor-specific CD8 +  T cell-mediated immune responses after TLR5 stimulation in a therapeutic cancer vaccine model (Nguyen et al., 2013). This evidence concerns the gene TLR5 and neoplasm.